中惠生物更新招股书:仅一款疫苗商业化,市场已成“红海”

经济观察网
Jul 27

7月24日,江苏中慧元通生物科技股份有限公司(下称“中慧生物”)在港交所再次递表,招股书显示,公司目前仅有一款四价流感病毒亚单位疫苗实现商业化,且尚未实现年度盈利。中慧生物2025年1月23日递表后失效,此次是再次申请。此前,中慧生物于2025年6月25日获中国证监会国际司境外发行上市备案通知书,拟发行不超过1.38亿股境外上市普通股。中慧生物有两款核心产品,包括冻干人用狂犬病疫苗(人二倍体细胞)...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10